21-Nov-2024	Initial Director's Interest Notice - PL

21-Nov-2024	Final Director's Interest Notice x 2

20-Nov-2024	Application for quotation of securities - ILA

19-Nov-2024	Replacement - Results of AGM

19-Nov-2024	Results of AGM

19-Nov-2024	Annual General Meeting MD Presentation

18-Nov-2024	Clinical trial progress update

15-Nov-2024	Phillip Lynch appointed Executive Chairman

13-Nov-2024	Application for quotation of securities - ILA

12-Nov-2024	Investor Presentation

11-Nov-2024	Board changes

7-Nov-2024	Investor information session

6-Nov-2024	Application for quotation of securities - ILA

31-Oct-2024	Quarterly Activities & Cashflow Report

30-Oct-2024	Application for quotation of securities - ILA

23-Oct-2024	Application for quotation of securities - ILA

18-Oct-2024	Letter to Shareholders, Notice of AGM & Proxy Form

16-Oct-2024	Application for quotation of securities - ILA

15-Oct-2024	Becoming a substantial holder

15-Oct-2024	Change in substantial holding

15-Oct-2024	Change in substantial holding

15-Oct-2024	Becoming a substantial holder

11-Oct-2024	Cleansing Notice

11-Oct-2024	Application for quotation of securities - ILA

9-Oct-2024	Application for quotation of securities - ILA

8-Oct-2024	Investor presentation

4-Oct-2024	Investor webinar

3-Oct-2024	Proposed issue of securities - ILA

3-Oct-2024	Island completes $3.5m Placement

3-Oct-2024	Phase 2a PROTECT clinical trial dosed & Investor webinar

1-Oct-2024	Trading Halt

23-Sep-2024	Final Director's Interest Notice - DB

23-Sep-2024	Initial Director's Interest Notice - CN

19-Sep-2024	Investor presentation

19-Sep-2024	Board changes

18-Sep-2024	Application for quotation of securities - ILA

11-Sep-2024	Binding LOI for proposed acquisition of Galidesivir

29-Aug-2024	Appendix 4G and Corporate Governance Statement

29-Aug-2024	Annual Report to shareholders

29-Aug-2024	Preliminary Final Report

27-Aug-2024	Phase 2a/b clinical trial update

7-Aug-2024	ISLA-101 Phase 2a/b clinical trial progresses

7-Aug-2024	Application for quotation of securities - ILA

31-Jul-2024	Quarterly Activities & Cashflow Report

19-Jul-2024	Resignation of Joint Company Secretary

10-Jul-2024	Investor Presentation - Bioshares

3-Jul-2024	ISLA-101 Clinical Program Update

3-Jul-2024	Non-binding term sheet signed with BioCryst

1-Jul-2024	Trading Halt

26-Jun-2024	Change of Director Interest Notice - DF

26-Jun-2024	Application for quotation of securities - ILA

21-Jun-2024	Change in substantial holding

21-Jun-2024	Application for quotation of securities - ILA

19-Jun-2024	Application for quotation of securities - ILA

12-Jun-2024	Application for quotation of securities - ILA

6-Jun-2024	Piggy Back Options Closing Date Reminder

6-Jun-2024	Notification regarding unquoted securities - ILA

5-Jun-2024	Application for quotation of securities - ILA

3-Jun-2024	New data leads to proposed ISLA-101 Phase 2 efficiencies

3-Jun-2024	Investor Presentation

29-May-2024	Application for quotation of securities - ILA

8-May-2024	Grant funding to directly support Phase 2a trial

6-May-2024	Change of Director's Interest Notice x5

6-May-2024	Notification of cessation of securities - ILA

30-Apr-2024	Quarterly Appendix 4C and Activities Report

22-Apr-2024	Investor Presentation - Asia Bio Partnering

17-Apr-2024	Application for quotation of securities - ILA

16-Apr-2024	Positive data from ISLA-101 Single Ascending Dose study

4-Apr-2024	Change in substantial holding

4-Apr-2024	Change in substantial holding

4-Apr-2024	Change of Director's Interest Notice x 5

3-Apr-2024	Change in substantial holding

2-Apr-2024	Top 20 Option Holders & Distribution Schedule

2-Apr-2024	Security Class Reinstatement to Quotation ILAO

27-Mar-2024	Updated Trading Policy

27-Mar-2024	Application for quotation of securities - ILA

26-Mar-2024	Security Class Suspension from Quotation ILAO

26-Mar-2024	Application for quotation of securities - ILA

21-Mar-2024	Update - Proposed issue of securities - ILA

19-Mar-2024	Results of Rights Issue Offer

5-Mar-2024	Despatch of Rights Issue documentation

5-Mar-2024	Letter to ineligible shareholders

26-Feb-2024	Update - Proposed issue of securities - ILA

26-Feb-2024	Letter to Optionholders

26-Feb-2024	Letter to Eligible Shareholders

26-Feb-2024	Target Market Determination

26-Feb-2024	Proposed issue of securities - ILA

26-Feb-2024	Prospectus

26-Feb-2024	$1.95million Fully Underwritten Rights Issue

26-Feb-2024	Appendix 4D & Half-Year Financial Statements

22-Feb-2024	Trading Halt

6-Feb-2024	Island investor presentation

6-Feb-2024	Dosing complete in ISLA-101 SAD study

31-Jan-2024	Quarterly Activity Report and Appendix 4C

19-Jan-2024	Third cohort dosed in ISLA-101 Single Ascending Dose study

11-Jan-2024	Notification of cessation of securities - ILA

22-Dec-2023	Approval to commence dosing 3rd cohort of ISLA-101 SAD study

15-Dec-2023	R&D Tax Incentive loan facility secured with Radium Capital

12-Dec-2023	Second cohort dosed in ISLA-101 Single Ascending Dose study

1-Dec-2023	Company Secretary Appointment/Resignation

24-Nov-2023	Island doses first cohort in ISLA-101 clinical trial

16-Nov-2023	Replacement Constitution

16-Nov-2023	Replacement - Results of AGM

16-Nov-2023	Results of AGM

16-Nov-2023	Annual General Meeting MD Presentation

13-Nov-2023	Screening commences for ISLA-101 Single Ascending Dose Study

10-Nov-2023	Island receives R&D tax refund for FY2023

7-Nov-2023	Island receives ethics approval for ISLA-101 study

6-Nov-2023	ILA releases updated investor presentation

2-Nov-2023	ILA granted key Australian patent for ISLA-101

31-Oct-2023	Island Annual General Meeting online link for shareholders

30-Oct-2023	Quarterly Activity Report & Appendix 4C

13-Oct-2023	Annual Report to Shareholders

13-Oct-2023	Letter to Shareholders, Notice of AGM & Proxy Form

26-Sep-2023	Date of AGM & Closing Date for Director Nominations

25-Sep-2023	ISLA-101 Single Ascending Dose study update

13-Sep-2023	Island Pharmaceuticals granted key U.S. patent for ISLA-101

30-Aug-2023	Appendix 4G

30-Aug-2023	Corporate Governance Statement

30-Aug-2023	Appendix 4E & Annual Report

31-Jul-2023	Quarterly Activity Report & Appendix 4C

7-Jul-2023	US grant funding to support ISLA-101 clinical development

16-May-2023	Island receives FDA go-ahead for ISLA-101 program

27-Apr-2023	Replacement - Change in substantial holding

27-Apr-2023	Change in substantial holding

27-Apr-2023	Quarterly Activity Report & Appendix 4C

17-Apr-2023	Island submits responses to FDA questions for ISLA-101

13-Apr-2023	Application for quotation of securities - ILA

4-Apr-2023	Appendix 3Y - Albert Hansen

4-Apr-2023	Notification of cessation of securities - ILA

3-Apr-2023	Release of Securities from Escrow

23-Feb-2023	Appendix 4D & Half-Year Financial Statements

7-Feb-2023	Change in substantial holding

1-Feb-2023	ILA receives additional FDA feedback on IND for ISLA 101

30-Jan-2023	Quarterly Activity Report & Appendix 4C

20-Jan-2023	Island receives FDA feedback on Phase 2a clinical study

28-Dec-2022	ILA submits IND to US FDA for Phase 2a PEACH clinical trial

19-Dec-2022	Notice of Change of Auditor

15-Dec-2022	Island online investor briefing presentation

15-Dec-2022	IRB approval received for ISLA101 Phase 2a clinical trial

15-Dec-2022	ISLA101 drug product achieves stability milestone

12-Dec-2022	Island investor briefing invitation

5-Dec-2022	ISLA-101 trial update and investor presentation

29-Nov-2022	Island to present at World Antiviral Congress 2022

21-Nov-2022	Change in substantial holding

17-Nov-2022	Results of AGM

17-Nov-2022	Annual General Meeting MD Presentation

16-Nov-2022	ILA granted key Canadian patent for ISLA-101

14-Nov-2022	Positive analytical results for ISLA-101 capsules

3-Nov-2022	Island ShareCafe webinar presentation

31-Oct-2022	Quarterly Activity Report & Appendix 4C

28-Oct-2022	ISLA-101 manufacturing progress

17-Oct-2022	Annual Report to Shareholders

17-Oct-2022	Letter to Shareholders, Notice of AGM & Proxy Form

29-Sep-2022	Date of AGM & Closing Date for Director Nominations

25-Aug-2022	Appendix 4G

25-Aug-2022	Corporate Governance Statement

25-Aug-2022	Appendix 4E & Annual Report

4-Aug-2022	Appendix 3Y - David Foster

28-Jul-2022	Quarterly Activity Report & Appendix 4C

21-Jul-2022	Notification regarding unquoted securities - ILA

19-Jul-2022	Dr Amy Patick joins Island Scientific Advisory Board

22-Jun-2022	Appendix 3Y - David Foster

15-Jun-2022	Island to present at BIO International Convention

15-Jun-2022	ISLA-101 manufacturing and timeline update

28-Apr-2022	Change in substantial holding

28-Apr-2022	Quarterly Activity Report & Appendix 4C

5-Apr-2022	Updated Investor Presentation & Conference Participation

31-Mar-2022	Change in substantial holding

25-Mar-2022	Release of Securities from Escrow

24-Feb-2022	Appendix 4D & Half-Year Financial Statements

17-Feb-2022	Application for quotation of securities - ILA

10-Feb-2022	Updated Investor Presentation & Webinar Invitation

1-Feb-2022	Change in substantial holding

31-Jan-2022	Release of Securities from Escrow

27-Jan-2022	Quarterly Activity Report & Appendix 4C

4-Jan-2022	Island executes PEACH clinical study CRO agreement

25-Nov-2021	Change in substantial holding

18-Nov-2021	Appendix 3Y - Anna Lavelle

18-Nov-2021	Appendix 3Y - Albert Hansen

18-Nov-2021	Appendix 3Y - David Brookes

18-Nov-2021	Cleansing Notice

18-Nov-2021	Application for quotation of securities - ILA

17-Nov-2021	Results of Annual General Meeting

17-Nov-2021	Annual General Meeting MD Presentation

17-Nov-2021	Annual General Meeting Chair Address

9-Nov-2021	ISLA-101 Phase 2a clinical trial update

28-Oct-2021	Quarterly Activity Report & Appendix 4C

19-Oct-2021	Change in substantial holding

14-Oct-2021	Proposed issue of securities - ILA

14-Oct-2021	Annual Report to shareholders

14-Oct-2021	Letter to Shareholders & Notice of Annual General Meeting

13-Oct-2021	Change in substantial holding

11-Oct-2021	Updated Investor Presentation

6-Oct-2021	Release of Securities from Voluntary Escrow

29-Sep-2021	Date of AGM & Closing Date for Director Nominations

20-Sep-2021	Island updates API agreement

26-Aug-2021	Appendix 4G

26-Aug-2021	Corporate Governance Statement

26-Aug-2021	Appendix 4E & Annual Report

23-Aug-2021	Griffith Uni Anti-Viral Molecule Screening Collaboration

23-Aug-2021	Change in substantial holding

18-Aug-2021	Island granted key Australian patent for ISLA-101

11-Aug-2021	Becoming a substantial holder

28-Jul-2021	Quarterly Activity Report & Appendix 4C

22-Jul-2021	Island secures API - shortens timeline to clinical trials

9-Jun-2021	ASEAN Dengue Day - Investor briefing notification

19-May-2021	Island Pharmaceuticals granted key United States patent

13-Apr-2021	Island lists on the ASX following oversubscribed IPO

13-Apr-2021	Island Pharmaceuticals IPO Investor Presentation

13-Apr-2021	Appendix 3X - Anna Lavelle

13-Apr-2021	Appendix 3X - David Brookes

13-Apr-2021	Appendix 3X - Paul MacLeman

13-Apr-2021	Appendix 3X - David Foster

13-Apr-2021	Appendix 3X - Albert Hansen

13-Apr-2021	Becoming a substantial holder

13-Apr-2021	Becoming a substantial holder

13-Apr-2021	Becoming a substantial holder

9-Apr-2021	Pre-Quotation Disclosure Statement

9-Apr-2021	Top 20 Holders

9-Apr-2021	Distribution Schedule

9-Apr-2021	Securities Trading Policy

9-Apr-2021	U.S. Option Terms

9-Apr-2021	Option Terms

9-Apr-2021	Employee Option Terms

9-Apr-2021	Employee Incentive Plan Rules

9-Apr-2021	Financial Report 30 June 2020

9-Apr-2021	Financial Report half year ended 31 December 2020

9-Apr-2021	Isla Pharmaceuticals, Inc. Financial Report 31 Dec 20 & 19

9-Apr-2021	Isla Pharmaceuticals, Inc. Financial Report 31 December 2018

9-Apr-2021	Constitution

9-Apr-2021	Prospectus

9-Apr-2021	Appendix 1A and Information Form and Checklist

9-Apr-2021	Admission and Commencement of Official Quotation